There are 95 resources available
978P - Post-progression outcomes of advanced HCC patients (aHCC pts) treated with first-line atezolizumab/bevacizumab (A/B)
Presenter: Claudia Fulgenzi
Session: Poster session 18
1007P - Network meta-analysis (NMA) of lenvatinib vs key comparators in first-line unresectable hepatocellular carcinoma (uHCC)
Presenter: David Trueman
Session: Poster session 18
1708P - The registration pathways in China for globally developed novel anticancer drugs
Presenter: Da-wei Wu
Session: Poster session 23
987P - Safety and efficacy of lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Korea
Presenter: Wonseok Kang
Session: Poster session 18
132MO - Molecular profiling of 991 prospectively recruited rare cancers patients in EUROPE: First results of ARCAGEN – an EORTC-SPECTA and EURACAN study
Presenter: Marie Morfouace
Session: Mini oral session - Basic science & translational research
Resources:
Abstract
Slides
Webcast
1324MO - CNS outcomes of lazertinib vs gefitinib in EGFR-mutated advanced NSCLC: A LASER301 subset analysis
Presenter: Ross Soo
Session: Mini oral session 2 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA100 - CUP-ONE trial: A prospective double-blind validation of molecular classifiers in the diagnosis of cancer of unknown primary and clinical outcomes
Presenter: Harpreet Wasan
Session: Mini oral session - Basic science & translational research
Resources:
Abstract
Slides
Webcast